MILLER MICHAEL PATRICK 4

What Happened

• Michael Patrick Miller, a member of Rigel Pharmaceuticals' Board of Directors, was granted a derivative award of 12,000 shares on February 1, 2026. The Form 4 reports an acquisition price of $0.00, indicating this was a company equity award (an option/award) rather than a market purchase. There was no sale or exercise reported in this filing.

Key Details

• Transaction date: 2026-02-01; Filing date: 2026-02-03 (file appears timely, within the Form 4 reporting window).
• Reported amount: 12,000 derivative shares; acquisition price shown as $0.00 (no cash paid at grant).
• Shares owned following the transaction: Not stated in the filing.
• Footnote: The award vests in equal monthly installments beginning Feb 1, 2026 and continuing until the date of the annual meeting at which the reporting person is first scheduled to be considered for election, subject to continuous board service.
• No 10b5-1 plan, tax withholding, or cashless exercise noted in this filing.

Context

• This is an award/option grant to a director and does not reflect an open‑market buy or sell; such grants are routine compensation for board service. Because the award vests over time, future filings (exercises or sales) may follow once vesting or exercise events occur.